Further investigations are required to clarify the biological mechanisms to evaluate whether IL-8 inhibition in pancreatic cancer serves as a promising therapeutic strategy for attenuating CC and has the potential to retard disease progression. This evidence concerns the gene CXCL8 and pancreatic neoplasm.